Syndax Pharmaceuticals, Inc.
Syndax is determined to realize a future in which people with cancer live longer and better than ever before. Syndax’s pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, in development for the treatment of patients with MLLr or mNPM1 acute leukemias, and axatilimab, an investigational monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, in development for the treatment of patients with chronic Graft versus Host Disease.